Dong-A Pharmaceutical
Manufacturing · South Korea · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
64 Cheonho-daero, Seoul, Seoul, South Ko...Phone Number
+82 29208114Website
www.donga.co.krRevenue
$466.4 MillionStock Symbol
27412702Industry
About Dong-A Pharmaceutical
Dong-A Pharmaceutical Org Chart
Is Dong-A Pharmaceutical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Dong-A Pharmaceutical launches new products
Check if Dong-A Pharmaceutical has recently received funding, and reach out quickly before it becomes old news!
Dong-A Pharmaceutical, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Dong-A Pharmaceutical has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Dong-A Pharmaceutical
Click to see if Dong-A Pharmaceutical had a recent Job posting/layoffs
Earning: See what the market has to say on Dong-A Pharmaceutical recently announced quarterly report
Check out if Dong-A Pharmaceutical is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Dong-A Pharmaceutical as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Dong-A Pharmaceutical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Dong-A Pharmaceutical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Dong-A Pharmaceutical.
Dong-A Pharmaceutical Tech Stack
Dong-A Pharmaceutical News & Media
Dong-A ST Demonstrates Therapeutic Equivalence Between DMB-3115 and Stelara in Global Phase III
SEOUL, South Korea--(BUSINESS WIRE)-- #DMB3115--Dong-A ST announced that the therapeutic equivalence and safety between DMB-3115 and Stelara were established in global phase III.Dong-A ST Signs License-out Deal with Polifarma of Türkiye for NESP® Biosimilar DA-3880
SEOUL, South Korea--(BUSINESS WIRE)-- #ARANESP--Dong-A ST licenses out the rights for the development and commercialization of NESP® Biosimilar DA-3880 in Türkiye, Brazil and Mexico to Polifarma.Dong-A ST and Beactica Therapeutics mutually agree to conclude oncology collaboration
Dong-A ST Co., Ltd. (170900: Korea SE), a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish precision oncology company, today announced that they have mutually agreed to terminate their collaboration and licensing agreement. The collaboration focused on developing novel candidate compounds against multiple cancer targets of mutual interest. The partnership has been productive, and multiple compound classes are now in various stages of lead generation and optimization. As parDong-A ST and Beactica Therapeutics Achieve Key Milestone in Their Collaboration to Develop New Cancer Treatments
Dong-A ST Co., Ltd. (170900: Korea SE), a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish drug discovery company, today announced that a lead compound meeting certain pre-defined criteria has been selected in their collaborative research programme aimed at developing first-in-class protein-protein interaction inhibitors for a target of therapeutic importance in cancer and other diseases.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Dong-A Pharmaceutical
Dong-A Socio Group is a professional healthcare organization that focuses on fulfilling social responsibility through various sectors including medical and digital healthcare, consumer products, logistics, IT services, and engineering. The company aims to enhance human health and well-being by providing specialized medical services, health function... Read More